References

Cure Arthritis Naturally

Beat Arthritis Naturally

Get Instant Access

Abrams JR, Lebwohl M, et al. (1999) CTLA4Ig-mediated blockade of T cell co-stimulation in patients with psoriasis vulgaris. J Clin Invest 103:1243 -1252 Antoni CE, Kavanaugh A, et al. (2005a) Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 52:1227-1236 Antoni C, Krueger GG, et al. (2005b) Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 64:1150 -1157 Baeten D, Kruithof E, et al. (2005) Infiltration of the synovial membrane with macrophage subsets and polymorphonu-clear cells reflects global disease activity in spondyloarthropathy. Arthritis Res Ther 7:R359-369 Bansback N, Barkham N, et al. (2004) The economic implications of TNF-inhibitors in the treatment of psoriatic arthritis. Arthritis Rheum 50 (Suppl 9):S509 Baraliakos X, Braun J (2006) Magnetic resonance imaging in spondyloarthropathies. Joint Bone Spine 73:1 -3 Bongartz T, Coras B, et al. (2005) Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label pilot study. Rheumatology (Oxford) 44:126129

D'Agostino MA, Said-Nahal R, et al. (2003) Assessment of peripheral enthesitis in the spondylarthropathies by ultra-sonography combined with power Doppler: a cross-sectional study. Arthritis Rheum 48:523-533 De Rycke L, Vandooren B, et al. (2005) Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy. Arthritis Rheum 52:2146-2158

De Simone C, Guerriero C, et al. (2003) Achilles tendinitis in psoriasis: clinical and sonographic findings. J Am Acad Dermatol 49:217-222 Eastmond CJ, Wright V (1979) The nail dystrophy of psoriatic arthritis. Ann Rheum Dis 38:226-228 Fransen J, Antoni C, et al. (2006) Performance of response criteria for assessing peripheral arthritis in patients with pso-riatic arthritis: Analysis of data from randomized, con trolled trials of two TNF inhibitors. Ann Rheum Dis (in press)

Gelfand JM, Gladman DD, et al. (2005) Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 53:573 Gibbs A, Gogarty M, et al. (2006) Moderate clinical response and absence of MRI or immunohistological change suggests that anakinra is ineffective in psoriatic arthritis. Arthritis Rheum 54 (Suppl 9):S719 Gladman DD (1998) Psoriatic arthritis. Rheum Dis Clin North

Am 24:829-844 Gladman D, Rahman P (2001) Psoriatic arthritis. In: Ruddy S, Harris ED, Sledge CB, Budd RC, Sarjent JS (eds) Kelly's textbook of rheumatology. WB Saunders, Philadelphia, pp 1071-1079

Gladman DD, Anhorn KA, et al. (1986) HLA antigens in psoriatic arthritis. J Rheumatol 13:586-592 Gladman DD, Farewell VT, et al. (1995) Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model. J Rheumatol 22:675-679 Gladman DD, Farewell VT, et al. (2003) HLA is a candidate region for psoriatic arthritis. evidence for excessive HLA sharing in sibling pairs. Hum Immunol 64:887-889 Gladman DD, Helliwell P, et al. (2004) Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum 50:24-35 Gladman D, Antoni C, et al. (2005) Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64 (Suppl 2):ii14-ii17 Guh D, Bansback N, et al. (2005) Improvement in health utility in patients with psoriatic arthritis treated with adalimumab (Humira). Ann Rheum Dis 64 (Suppl 3):401 Hansen KE, Hildebrand JP, et al. (2004) The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Rheumatol 31:1098-1102 Haraoui B, Keystone EC, et al. (2004) Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. J Rheumatol 31:2356-2359 Helliwell P, Taylor W (2005) Classification and diagnostic criteria for psoriatic arthritis. Ann Rheum Dis 64(Suppl 2):ii3-ii8

Helliwell PS, Wright V (2000) Psoriatic arthritis: clinical features. In: Klippel J, Dieppe P (eds) Rheumatology. Mosby, St. Louis, MO, pp 6.21.1 -6.21.8 Husted JA, Gladman DD, et al. (1997) Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis. J Rheumatol 24:511-517 Husted JA, Gladman DD, et al. (1998) Responsiveness of health status instruments to changes in articular status and perceived health in patients with psoriatic arthritis. J Rheumatol 25:2146-2155 Husted JA, Gladman DD, et al. (2001) Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum 45: 151-158

Jung JH, ZT, Kavanaugh A (2005) Other biologic therapy. In: Gordon KB, Ruderman E (eds) Psoriasis and psoriatic arthritis: An integrated approach. Springer-Verlag, Heidelberg, pp 223-234

Kane D, Greaney T, et al. (1999) Ultrasonography in the diagnosis and management of psoriatic dactylitis. J Rheumatol 26:1746-1751

Klauser A, Halpern EJ, et al. (2005) Inflammatory low back pain: high negative predictive value of contrast-enhanced color Doppler ultrasound in the detection ofinflamed sacro-iliac joints. Arthritis Rheum 53:440-444 Kraan MC, van Kuijk AW, et al. (2002) Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum 46:2776-2784 Kremer JM, Westhovens R, et al. (2003) Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 349:1907-1915 Krueger J, Bowcock A (2005) Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 64(Suppl 2): ii30-ii36

Krueger JG, Walters IB, Miyazawa M, et al. (2000) Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J Am Acad Dermatol 43:448-458 Krueger GG, Papp KA, Sough DB, et al. (2002) A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 47: 821-833

Krueger GG, Langley R, et al. (2006) Results of a phase II study of CNTO1275 in the treatment of psoriasis. Journal of American Academy of Dermatol 54(3):AB10 Kruithof E, Baeten D, et al. (2005) Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther 7:R569-580 Langley R, Krueger G, et al. (2005) Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 64(Suppl 2):ii18-ii23 Lebwohl M, Christophers E, et al. (2003a) An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 139:719-727 Lebwohl M, Tyring SK, et al. (2003b) A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 349:2004-2013

LebwohlM, Ting P, et al. (2005) Psoriasistreatment: traditional therapy. Ann Rheum Dis 64(Suppl 64):ii83-ii86 Leonard DG, O'Duffy JD, et al. (1978) Prospective analysis of psoriatic arthritis in patients hospitalized for psoriasis. Mayo Clin Proc 53:511-518 Marra CA (2005) Valuing health states and preferences of patients. Ann Rheum Dis 64 (Suppl 3):36 McGonagle D, Gibbon W, et al. (1998) Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondylarthropathy. Arthritis Rheum 41:694 - 700 McInnes IB, Gracie JA (2004) Interleukin-15: a new cytokine target for the treatment of inflammatory diseases. Curr Opin Pharmacol 4:392-397 McInnes IB, Illei GG, et al. (2001) IL-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis. J Immunol 167:4075-4082

Mease PJ (2003) Psoriatic arthritis/psoriasis. In: Smolen J, Lipsky PE (eds) Targeted therapies in rheumatology. Martin Dunitz, London, pp 525-548 Mease PJ (2004a) Recent advances in the management of psoriatic arthritis. Curr Opin Rheumatol 16:366-370 Mease P (2004b) TNFalpha therapy in psoriatic arthritis and psoriasis. Ann Rheum Dis 63:755-758 Mease P (2004c) Targeting therapy in psoriatic arthritis. Drug

Discovery Today 1:389 -396 Mease P, Antoni C (2005) Psoriatic arthritis treatment: biological response modifiers. Ann Rheum Dis 64(Suppl 2):ii78-ii82 Mease PJ, Goffe BS (2005) Diagnosis and treatment of psoriatic arthritis. J Am Acad Dermatol 52:1 -19 Mease P, van der Heidje D (2006) Joint damage in psoriatic arthritis: How is it assessed and can be prevented? International J Advances in Rheumatol 4:38-48 Mease PJ, Goffe BS, et al. (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356:385-390

Mease P, Kavanaugh A, et al. (2004a) Infliximab improves psoriasis regardless of arthritis response in patients with active psoriatic arthritis: results from IMPACT 2 Trial [abstract]. Arthritis Rheum 50(Suppl 9):S616 Mease P, Kivitz A, et al. (2004b) Etanercept treatment ofpsori-atic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 50:2264-2272 Mease P, Ruderman EM, et al. (2004c) Etanercept in psoriatic arthritis: sustained improvement in joint and skin disease and inhibition of radiographic progression at 2 years [abstract]. Ann Rheum Dis 63(Suppl 1):99 Mease P, Antoni C, et al. (2005a) Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 64(Suppl 2):ii49-ii54 Mease P, Gladman D, et al. (2005b) Efficacy of alefacept in combination with methotrexate in the treatment of psoriatic arthritis [abstract]. Ann Rheum Dis 64(Suppl 3):324 Mease P, Gladman D, et al. (2005c) Alefacept in combination with methotrexate for the treatment of psoriatic arthritis. Arthritis Rheum 52 (Suppl 9):S280 Mease P, Gladman D, et al. (2005d) Adalimumab in the treatment of patients with moderately to severely active psoriatic arthritis: results of ADEPT. Arthritis Rheum 58:3279-3289 Mease P, Gladman D, et al. (2006a) Alefacept (Amevive®) in combination with methotrexate for the treatment ofpsoriat-ic arthritis: results for a randomized, double-blind, placebo-controlled study. Arth Rheum 54:1638-1645 Mease P, Kivitz AJ, et al. (2006b) Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 33:712-721

Mease P and Menter A (2006c) Quality of life issues in psoriasis and psoriatic arthritis: Outcome measures and therapies from a dermatological perspective. Journal of American Academy of Dermatol 54:685 - 704 Menter A and Mease P (2004) The pathogenesis and treatment of psoriasis. In: Schiff M (eds) Rheumatology Educational Initiative (REDI): making a difference in rheumatology. Early and aggressive treatment = better outcomes for today's patients. Veritas Institute for Medical Education, Hasbrouck Heights, NJ, pp 231 -252 Moll J, Wright V (1973) Psoriatic arthritis. Semin Arthritis

Rheum 3:55-78 Moll JM Wright V (1973) Familial occurrence of PsA. Ann

Rheum Dis 32:181-201 Nash P, Clegg DO (2005) Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis 64(Suppl 2):ii74-ii77

Nishimoto N, Yoshizaki K, et al. (2004) Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 50:1761 -1769 Offidani A, Cellini A, et al. (1998) Subclinical joint involvement in psoriasis: magnetic resonance imaging and X-ray findings. Acta Derm Venereol 78:463-465 Ory P, Gladman DD, et al. (2005) Psoriatic arthritis and imaging. Ann Rheum Dis 64(Suppl 2):ii55-ii57 Papp K, Mease P, et al. (2004) Efalizumab in patients with psoriatic arthritis: results of a phase II randomized doubleblind placebo controlled study. International Psoriasis Symposium, Toronto Rahman P, Elder J (2005) Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis64(Suppl2):ii37-ii9 Rahman P, Gladman DD, Schentag C, Petronis A (1999) Excessive paternal transmission in psoriatic arthritis. Arthritis Rheum 42:1228-1231 Reich K, Garbe C, et al. (2001) Response of psoriasis to inter-leukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal interleu-kin-8/CXCR2 pathway and normalization of keratinocyte maturation. J Invest Dermatol 116:319-329 Ritchlin CT (2005) Pathogenesis of psoriatic arthritis. Curr

Opin Rheumatol 17:406 - 412 Ritchlin C, Anandarajaha A, et al. (2004) Preliminary data from a study of adalimumab in the treatment of psoriatic arthritis [abstract]. Ann Rheum Dis 63(Suppl 1):403 Salonen S (2003) The EUROPSO psoriasis patient study: treatment history and satisfaction reported by 17,900 members of European psoriasis patients associations (poster). Spring Symposium of the European Academy of Dermatology and Venereology, Malta Sege-Peterson K, Winchester R (1999) Psoriatic arthritis. In: Freedberg IM, Eisen AZ, Wolff K, et al. (eds) Fitzpatrick's dermatology in general medicine. McGraw Hill, New York, pp 522-523

Shbeeb M, Uramoto KM, et al. (2000) The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982 -1991. J Rheumatol 27:1247-1250

Singh A, Mease P, et al. (2005) Health Assessment Questionnaire has similar psychometric properties in psoriatic arthritis and rheumatoid arthritis. Arthritis Rheum 52 (Suppl 9):S402

Taylor W, Gladman D, et al. (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54(8):2665-2673 Taylor W, Marchesoni A, et al. (2004) A comparison of the performance characteristics of classification criteria for the diagnosis of psoriatic arthritis. Semin Arthritis Rheum 34: 575-584

Taylor WS, Helliwell PS, Gladman DD, Mease P, Mielants M, Marchesoni A (2005) A validation of current classification criteria for the diagnosis of psoriatic arthritis - preliminary results of the CASPAR study. Ann Rheum Dis 64:107 Trepicchio WL, Ozawa M, et al. (1999) Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest 104:15271537

Utset TO, Auger JA, et al. (2002) Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J Rheumatol 29: 1907-1913

van den Bosch F, Reece R, et al. (2006) Adalimumab (Humira®) is effective and safe in treating psoriatic arthritis (PsA) in real-life clinical practice: Preliminary results of the STEREO trial. Arthritis Rheum 54(Suppl 9):S719-S720 van der Heidje D, Gladman D, et al. (2005a) Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis: 54 week results from IMPACT 2. Arthritis Rheum 52 (Suppl 9):S281 van der Heijde D, Kavanaugh A, et al. (2005b) Infliximab inhibits progression of radiographic damage in patients with active psoriatic damage in patients with active psoriatic arthritis: Results from IMPACT 2 trial. Ann Rheum Dis 64(Suppl 3):109

van der Heijde D, Sharp J, et al. (2005c) Psoriatic arthritis imaging: a review of scoring methods. Ann Rheum Dis 64(Suppl 2):ii61-ii64 Veale D, Ritchlin C, et al. (2005) Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis 65(Suppl 2):ii26-ii29

Wakefield RJ, Balint PV, et al. (2005) Musculoskeletal ultrasound including definitions for ultrasonographic pathology. J Rheumatol 32:2485-2487 Winterfield L, Menter A, et al. (2005) Psoriasis treatment: current and emerging directed therapies. Ann Rheum Dis 64(Suppl 64):ii87-ii90 Zenz R, Eferl R, et al. (2005) Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 437:369-375

Was this article helpful?

0 0
Natural Arthritis Pain Remedies

Natural Arthritis Pain Remedies

It's time for a change. Finally A Way to Get Pain Relief for Your Arthritis Without Possibly Risking Your Health in the Process. You may not be aware of this, but taking prescription drugs to get relief for your Arthritis Pain is not the only solution. There are alternative pain relief treatments available.

Get My Free Ebook


Post a comment